Clinical questions adapted
| Initial management |
| Home treatment vs hospital treatment in patients with uncomplicated DVT |
| Home treatment vs hospital treatment in patients with PE and low risk of complication |
| DOACs vs VKAs in patients with VTE |
| Thrombolytic therapy plus anticoagulation vs anticoagulation alone in patients with extensive proximal DVT |
| Thrombolytic therapy plus anticoagulation vs anticoagulation alone in patients with submassive PE |
| Compression stockings plus anticoagulation vs anticoagulation alone in patients with DVT and high risk of PTS |
| Secondary prevention: continuation of anticoagulation after primary treatment |
| D-dimer vs no D-dimer to decide duration of treatment in patients with unprovoked VTE |
| Prognostic scores vs no prognostic score to decide duration of treatment in patients with unprovoked VTE |
| Indefinite anticoagulation vs discontinuation in patients with unprovoked VTE |
| Indefinite anticoagulation vs discontinuation in patients with recurrent unprovoked VTE |
| Indefinite anticoagulation vs discontinuation in patients with VTE related to a chronic risk factor |
| Indefinite anticoagulation vs discontinuation in patients with recurrent VTE related to a transient risk factor |
| Aspirin vs anticoagulation in patients with VTE who are going to continue antithrombotic therapy |
| Lower-dose DOACs vs standard-dose DOACs in patients with VTE who are going to continue on anticoagulation |
| DOACs vs LMWH in patients with VTE during treatment with VKAs |
| Additional management issues |
| Continuation of aspirin vs discontinuation in patients VTE who initiate anticoagulation |
| Resumption of oral anticoagulation after an anticoagulation-related major bleeding |
| Four-factor PCCs or FFP in patients with VKA-related life-threatening bleeding |
| Initial management |
| Home treatment vs hospital treatment in patients with uncomplicated DVT |
| Home treatment vs hospital treatment in patients with PE and low risk of complication |
| DOACs vs VKAs in patients with VTE |
| Thrombolytic therapy plus anticoagulation vs anticoagulation alone in patients with extensive proximal DVT |
| Thrombolytic therapy plus anticoagulation vs anticoagulation alone in patients with submassive PE |
| Compression stockings plus anticoagulation vs anticoagulation alone in patients with DVT and high risk of PTS |
| Secondary prevention: continuation of anticoagulation after primary treatment |
| D-dimer vs no D-dimer to decide duration of treatment in patients with unprovoked VTE |
| Prognostic scores vs no prognostic score to decide duration of treatment in patients with unprovoked VTE |
| Indefinite anticoagulation vs discontinuation in patients with unprovoked VTE |
| Indefinite anticoagulation vs discontinuation in patients with recurrent unprovoked VTE |
| Indefinite anticoagulation vs discontinuation in patients with VTE related to a chronic risk factor |
| Indefinite anticoagulation vs discontinuation in patients with recurrent VTE related to a transient risk factor |
| Aspirin vs anticoagulation in patients with VTE who are going to continue antithrombotic therapy |
| Lower-dose DOACs vs standard-dose DOACs in patients with VTE who are going to continue on anticoagulation |
| DOACs vs LMWH in patients with VTE during treatment with VKAs |
| Additional management issues |
| Continuation of aspirin vs discontinuation in patients VTE who initiate anticoagulation |
| Resumption of oral anticoagulation after an anticoagulation-related major bleeding |
| Four-factor PCCs or FFP in patients with VKA-related life-threatening bleeding |